(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX) announced that the U.S. FDA has approved its Epinephrine injection USP, 1 mg/mL, in both single-dose and multi-dose for use in U.S. hospitals.
BRIDGEWATER, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has ...
Many Medicare drug plans cover generic epinephrine auto-injectors, and some may also cover EpiPen. Medicare coverage through a Part D prescription drug plan depends on the plan details and other ...
Physicians identified key improvements for adrenaline auto-injectors, including longer shelf life and easier use, improving ...
The approval expands Amneal’s injectables portfolio with an essential medicine used in hospitals for emergency and perioperative care. Epinephrine is a non-selective alpha and beta adrenergic agonist.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results